Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria

Ítems similars

• Treatment with a Farnesyltransferase Inhibitor Improves Survival in Mice with a Hutchinson-Gilford Progeria Syndrome Mutation
  per: Yang, Shao H., et al.
  Publicat: (2007)
• Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated
  per: Yang, Shao H., et al.
  Publicat: (2008)
• Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin
  per: Yang, Shao H., et al.
  Publicat: (2011)
• A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation
  per: Yang, Shao H., et al.
  Publicat: (2006)
• Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson–Gilford progeria syndrome mutation
  per: Yang, Shao H., et al.
  Publicat: (2005)